Boxcar Partners

Immuneering Corporation is a biopharmaceutical company specializing in genetic, genomic, and proteomic data analysis services for pharmaceutical companies. It focuses on generating biological insights that enhance the clinical and commercial success of medicines, particularly for patients with cancer, autoimmune diseases, and neurodegenerative conditions. Immuneering employs advanced methodologies such as microarray analysis, single-nucleotide polymorphism assessment, and next-generation sequencing to uncover difficult-to-find signals and formulate biological hypotheses. The company has over a decade of experience in translational bioinformatics, which informs its drug discovery programs and supports patient treatment response analysis. Immuneering's proprietary computational platform, known as Disease Cancelling Technology, underpins its capabilities, allowing for a comprehensive approach to drug development. Founded in 2008 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Immuneering operates as a subsidiary of Teva Pharmaceutical Industries Limited.